Imunon (IMNN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing non-viral DNA technology for immunotherapy and vaccines targeting cancer and infectious diseases.

• Lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, with Phase II completed and Phase 3 pivotal trial design finalized in alignment with FDA.

• Additional pipeline includes a COVID-19 booster vaccine (IMNN-101) in first-in-human studies.

• Recent warrant exchange transaction issued 2,921,000 shares, representing 19.98% of outstanding shares, to existing warrant holders.

Financial performance and metrics

• Net loss of $4.1 million for Q1 2025 and $18.6 million for FY 2024; cumulative net losses of approximately $411 million as of March 31, 2025.

• Cash and cash equivalents of $2.9 million as of March 31, 2025, down from $5.9 million at year-end 2024.

• Substantial doubt exists regarding ability to continue as a going concern, as noted by independent auditor.

Use of proceeds and capital allocation

• Estimated net proceeds of $10.9 million if maximum securities are sold, with proceeds to be used for general corporate purposes, clinical development of IMNN-001, capital expenditures, and working capital.

• Actual proceeds may be significantly less due to best-efforts structure and no minimum offering amount.